Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Mar 24, 2016; 6(1): 165-173
Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.165
Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.165
Heparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledge
Volker Assfalg, Norbert Hüser, Department of Surgery, Klinikum rechts der Isar der Technischen Universität München, D-81675 Munich, Germany
Author contributions: Both authors equally contributed to this paper with conception and design of the review, literature review and analysis, drafting and critical revision and editing and final approval of the final version.
Conflict-of-interest statement: The authors declare no conflicts of interest regarding this manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Volker Assfalg, MD, Department of Surgery, Klinikum rechts der Isar der Technischen Universität München, Ismaningerstr. 22, D-81675 Munich, Germany. volker.assfalg@tum.de
Telephone: +49-89-41402121 Fax: +49-89-41404870
Received: August 28, 2015
Peer-review started: August 31, 2015
First decision: November 24, 2015
Revised: December 18, 2015
Accepted: February 14, 2016
Article in press: February 16, 2016
Published online: March 24, 2016
Peer-review started: August 31, 2015
First decision: November 24, 2015
Revised: December 18, 2015
Accepted: February 14, 2016
Article in press: February 16, 2016
Published online: March 24, 2016
Core Tip
Core tip: Heparin-induced thrombocytopenia (HIT) II is a life-threatening complication of heparin therapy. Transplant recipients frequently are exposed to high doses of heparin before, during, and after transplantation. This review gives a systematic overview on the current scientific knowledge and existing publications on anti-platelet factor 4/heparin antibodies and HIT in transplant candidates and recipients.